{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:29:22Z","timestamp":1783110562445,"version":"3.54.6"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T00:00:00Z","timestamp":1238371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Patients with systemic lupus erythematosus (SLE), with or without end\u2010stage renal failure, are at increased risk of premature cardiovascular disease. Although statin therapy has been found to reduce cardiovascular risk in the general population, its effectiveness in kidney transplant recipients with SLE has not been examined. This study was undertaken to investigate the effect of fluvastatin on cardiac end points in a randomized controlled trial of renal transplant patients with SLE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with SLE were identified from among participants in the Assessment of Lescol in Renal Transplantation trial, a randomized, double\u2010blind, placebo\u2010controlled study of the effect of fluvastatin (40\u201380 mg\/day) on cardiovascular outcomes in renal transplant recipients. Patients were randomized to either a group receiving fluvastatin or a placebo group for the duration of the 5\u20136\u2010year trial, and then invited to continue in a 2\u2010year open\u2010label extension during which all participants, regardless of original group, received fluvastatin. Patients were followed up for a total of 7\u20138 years for assessment of the primary end point of major cardiac events, comprising nonfatal myocardial infarction, cardiac death, and coronary intervention procedures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fluvastatin reduced low\u2010density lipoprotein cholesterol levels by 29.2% (95% confidence interval [95% CI] 18.3\u201340%), from a mean \u00b1 SD of 4.0 \u00b1 0.9 mmoles\/liter to 2.8 \u00b1 1.1 mmoles\/liter, and total cholesterol by 19.6% (95% CI 11.7\u201327.5%), from 6.4 \u00b1 0.9 mmoles\/liter to 5.1 \u00b1 1.1 mmoles\/liter. Compared with placebo\u2010treated patients, patients randomized to receive fluvastatin exhibited a 73.4% reduction in the risk of major cardiac events (relative risk 26.6 [95% CI 5.9\u2013119.4], <jats:italic>P<\/jats:italic> = 0.064).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate that the effect of fluvastatin on cardiac events in renal transplant recipients with SLE is similar to that observed with statin therapy in the renal transplant population as a whole.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.24379","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T01:45:08Z","timestamp":1238463908000},"page":"1060-1064","source":"Crossref","is-referenced-by-count":52,"title":["Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo\u2010controlled study"],"prefix":"10.1002","volume":"60","author":[{"given":"Gudrun E.","family":"Norby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingar","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadollah","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallvard","family":"Holdaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11296"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678920811"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.01.038"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01105.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035611"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2201oa"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21441"},{"issue":"9","key":"e_1_2_6_12_2","first-page":"S520","article-title":"Lupus Atherosclerosis Prevention Study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo","volume":"54","author":"Petri M","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem186"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-004-0021-4"},{"issue":"9","key":"e_1_2_6_15_2","first-page":"S791","article-title":"The Health Improvement and Prevention Program (HIPP) in systemic lupus erythematosus shows preliminary benefits in reducing the estimated 8\u2010year risk of cardiovascular disease","volume":"54","author":"Fortin PR","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei142"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0593"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0341-6"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.24379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.24379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T12:10:49Z","timestamp":1696680649000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.24379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,30]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1002\/art.24379"],"URL":"https:\/\/doi.org\/10.1002\/art.24379","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,30]]}}}